

Axinn Represents Thermo Fisher in \$7.2 Billion Acquisition of Patheon

NEWS | LESS THAN 1 MIN READ


May 17, 2017

Axinn is representing Thermo Fisher Scientific Inc. in its \$7.2 billion acquisition of Patheon NV, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors. The Axinn team consists of John Harkrider and Mark Alexander.

Related People



Mark D. Alexander



John D. Harkrider

Related Services

Antitrust

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Health Care Transactions Program 2025
SPONSORSHIP ANTITRUST
- Five Healthcare Antitrust Topics to Watch at the Upcoming Health Care Transactions Conference in Nashville
AXINN VIEWPOINTS ANTITRUST

- IAM Live: Auto IP USA 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved